↓ Skip to main content

A hemodynamic model to guide blood pressure control during deliberate hypotension with sodium nitroprusside in children

Overview of attention for article published in Frontiers in Pharmacology, July 2015
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Above-average Attention Score compared to outputs of the same age and source (56th percentile)

Mentioned by

twitter
2 X users

Citations

dimensions_citation
12 Dimensions

Readers on

mendeley
25 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A hemodynamic model to guide blood pressure control during deliberate hypotension with sodium nitroprusside in children
Published in
Frontiers in Pharmacology, July 2015
DOI 10.3389/fphar.2015.00151
Pubmed ID
Authors

Jeffrey S. Barrett, Sarapee Hirankarn, Nick Holford, Gregory B. Hammer, David R. Drover, Carol A. Cohane, Brian Anderson, Erin Dombrowski, Tammy Reece, Anne Zajicek, Scott R. Schulman

Abstract

Sodium nitroprusside (SNP) has been widely used to control blood pressure in infants and children. The goals of this analysis were to develop models that describe the hemodynamic response to SNP dosing in pediatric patients; examine sources of variation in dose-response, defining age, and size dependencies; and determine vulnerable populations or patient subtypes that may elicit dosing modifications. A multi-center, randomized, double-blinded, parallel-group, dose-ranging, effect-controlled study, followed by an open-label dose titration of an intravenous infusion of SNP was undertaken in 203 pediatric subjects, who required deliberate hypotension or controlled normotension during anesthesia. A total of 3464 MAP measurements collected from 202 patients during the study's blinded phase, including baseline measurements up to 6 min prior to the blinded were available for analysis. A population K-PD model was developed with a one-compartment model assumed for SNP. Size differences in CL and V of the effect compartment were described using theory-based allometry. An inhibitory sigmoidal Emax model was used to describe the effect of SNP. A power function of age was used to describe age-related differences in baseline MAP. A mixture model of two groups with low and high EC50 was used to explain variability in MAP response. Change in MAP was characterized by a linear disease progression slope during the blinded phase. In the final population model, CL and V increased with weight, and baseline MAP increased with age. The effect compartment half-life of SNP was 13.4 min. The infusion rate producing 50% of Emax (ER50) at steady state for high EC50, was 0.34 μg/kg/min and for low EC50 0.103 μg/kg/min. The K-PD model well-describes initial dosing of SNP under controlled circumstances; model-based dosing guidance agrees with current practice. An initial titration strategy supported via algorithm-based feedback should improve maintenance of target MAP.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 25 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 25 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 6 24%
Researcher 6 24%
Student > Master 4 16%
Professor > Associate Professor 3 12%
Other 1 4%
Other 2 8%
Unknown 3 12%
Readers by discipline Count As %
Medicine and Dentistry 12 48%
Pharmacology, Toxicology and Pharmaceutical Science 3 12%
Agricultural and Biological Sciences 3 12%
Computer Science 1 4%
Economics, Econometrics and Finance 1 4%
Other 1 4%
Unknown 4 16%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 August 2015.
All research outputs
#15,289,793
of 22,818,766 outputs
Outputs from Frontiers in Pharmacology
#6,261
of 16,050 outputs
Outputs of similar age
#153,089
of 263,394 outputs
Outputs of similar age from Frontiers in Pharmacology
#27
of 65 outputs
Altmetric has tracked 22,818,766 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 16,050 research outputs from this source. They receive a mean Attention Score of 4.9. This one has gotten more attention than average, scoring higher than 60% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 263,394 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 41st percentile – i.e., 41% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 65 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 56% of its contemporaries.